3,514,649 Shares in Illumina, Inc. $ILMN Acquired by Primecap Management Co. CA

Primecap Management Co. CA bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,514,649 shares of the life sciences company’s stock, valued at approximately $617,981,000.

Several other hedge funds have also made changes to their positions in the company. Capital World Investors grew its position in shares of Illumina by 0.6% during the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after buying an additional 124,323 shares in the last quarter. BlackRock Inc. purchased a new position in Illumina during the 2nd quarter valued at about $3,374,423,000. State Street Corp increased its position in Illumina by 3.2% during the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock valued at $811,895,000 after purchasing an additional 190,324 shares during the period. WCM Investment Management LLC raised its holdings in shares of Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of Illumina by 30.3% in the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after purchasing an additional 1,028,099 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Trading Up 0.8%

Shares of NASDAQ:ILMN opened at $224.99 on Wednesday. The business’s 50-day moving average is $190.35 and its 200 day moving average is $153.78. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $226.84. The firm has a market capitalization of $33.97 billion, a P/E ratio of 41.98, a P/E/G ratio of 3.14 and a beta of 1.45. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In other Illumina news, Director Keith A. Meister sold 457,858 shares of Illumina stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Scott D. Ericksen sold 1,500 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $150.10, for a total value of $225,150.00. Following the completion of the transaction, the chief accounting officer directly owned 14,946 shares in the company, valued at $2,243,394.60. This represents a 9.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 2,095,958 shares of company stock worth $401,720,974. 2.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ILMN. Piper Sandler reiterated an “overweight” rating and set a $225.00 price objective (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. Canaccord Genuity Group boosted their price objective on shares of Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research note on Monday, August 3rd. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Barclays lifted their price target on Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a report on Friday, July 31st. Finally, Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.